Screener
Sutro Biopharma STRO Contract Liabilities, Non-Current
Contract Liabilities, Non-Current at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The source filing: Sutro Biopharma’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:30 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liability - current | 7,600 | 7,783 |
| Accrued expenses and other current liabilities | 42,973 | 34,581 |
| Total current liabilities | 70,811 | 75,133 |
| Deferred revenue - non-current | 1,233 | 2,028 |
| Operating lease liability - non-current | 6,032 | 7,891 |
| Deferred royalty obligation related to the sale of future royalties | 229,105 | 219,536 |
| Other non-current liabilities | 1,694 | 1,694 |
| Total liabilities | 308,875 | 306,282 |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's contract liabilities, non-current?
- Sutro Biopharma (STRO) reported contract liabilities, non-current of $1.23M in Q1 2026.
- How has Sutro Biopharma's contract liabilities, non-current changed year-over-year?
- Sutro Biopharma's contract liabilities, non-current decreased by 85.6% year-over-year, from $8.57M to $1.23M.
- What is the long-term trend for Sutro Biopharma's contract liabilities, non-current?
- Over 4 years (2020 to 2025), Sutro Biopharma's contract liabilities, non-current has grown at a -24.1% compound annual growth rate (CAGR), from $6.1M to $2.03M.
Ask your AI about Sutro Biopharma's contract liabilities, non-current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude